Pharmafile Logo

IPO

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

GSK concedes execs may have broken Chinese law

President of international operations suggests senior execs were involved in bribery scandal

- PMLiVE

Intellectual property threats in the BRIC markets

Compulsory licensing and other legal concerns for pharma in emerging markets

- PMLiVE

Four GSK execs held in China bribery probe

Ministry of Public Security says company has dispensed nearly $500m in bribes since 2007

China flag thumb

GSK staff ‘confess to bribery’, says China

Government claims staff offered kickbacks to state officials and doctors

- PMLiVE

GSK’s Botox sales in China under scrutiny says WSJ

Newspaper says it has reviewed company documents that discuss giving kickbacks to doctors to prescribe Botox

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

China flag thumb

Pharma nervous as China probes drug prices

Local affiliates of multinationals and domestic companies in the spot light

- PMLiVE

A tailored approach to the BRIC markets

Patience, long-term thinking and strategies that are tailored to each market are key to pharma success in the BRIC countries and other emerging markets

- PMLiVE

Building BRICs: pharma’s key emerging markets are becoming giants

The BRIC nations – Brazil, Russia, India and China – for so long the leading lights of the emerging markets movement, may soon need to relinquish their 'emerging' tag and...

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links